Health Care & Life Sciences » Biotechnology | Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
47,167.00
50,561.00
41,097.00
47,159.00
89,912.00
74,908
SG&A Expense
129,880.00
222,849.00
318,055.00
456,616.00
576,633.00
881,344
EBIT
92,942.00
184,214.00
296,008.00
424,587.00
500,088.00
814,673
Unusual Expense
-
220,766.00
-
-
-
20,564
Non Operating Income/Expense
47.00
1,817.00
76.00
7,371.00
2,222.00
4,173
Interest Expense
-
-
-
1,200.00
800.00
-
Pretax Income
91,920.00
400,604.00
290,073.00
410,108.00
490,874.00
760,674
Income Tax
2,695.00
40,209.00
-
-
-
823
Consolidated Net Income
89,225.00
360,395.00
290,073.00
410,108.00
490,874.00
761,497
Net Income
89,225.00
360,395.00
290,073.00
410,108.00
490,874.00
761,497
Net Income After Extraordinaries
89,225.00
360,395.00
290,073.00
410,108.00
490,874.00
761,497
Net Income Available to Common
89,225.00
360,395.00
290,073.00
410,108.00
490,874.00
761,497
EPS (Basic)
1.45
4.85
3.45
4.79
5.42
7.57
Basic Shares Outstanding
61,551.00
74,278.00
83,992.00
85,596.00
90,554.00
100,590
EPS (Diluted)
1.45
4.85
3.45
4.79
5.42
7.57
Diluted Shares Outstanding
61,551.00
74,278.00
83,992.00
85,596.00
90,554.00
100,590
EBITDA
82,713.00
172,288.00
276,958.00
409,457.00
486,721.00
808,238
Non-Operating Interest Income
1,069.00
2,559.00
5,859.00
8,308.00
12,236.00
29,262

About Alnylam Pharmaceuticals

View Profile
Address
300 Third Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.alnylam.com
Updated 07/08/2019
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.